Related Experiment Videos
Dalteparin sodium.
1University of Calgary, Thrombosis Research Unit, Foothills Hospital, AB, Canada. jeanne.sheldon@crha-health.ab.ca
Expert Opinion on Pharmacotherapy
|October 5, 2001
Summary
Dalteparin sodium, a low molecular weight heparin, offers improved bioavailability and prolonged antithrombotic activity for preventing and treating thrombotic disorders. Its efficacy has led to international approval for various clinical indications.
Area of Science:
- Pharmacology
- Thrombosis Research
Background:
- Dalteparin sodium is a low molecular weight heparin (LMWH) with advantages over unfractionated heparin (UFH).
- Key benefits include enhanced bioavailability via subcutaneous injection and prolonged antithrombotic effects.
- Its pharmacokinetic profile allows for once-daily administration, correlating with body weight.
Purpose of the Study:
- To review the extensive clinical trial data for dalteparin sodium.
- To assess its approved and investigational indications in thrombotic disorders.
Main Methods:
- Analysis of data from numerous well-designed randomized clinical trials.
- Evaluation of studies investigating dalteparin sodium in specific patient populations and conditions.
Main Results:
- Dalteparin sodium is internationally approved for a broad range of indications, including post-surgery thromboembolism prevention.
- Clinical trials have explored its use in maintaining graft patency, long-term deep vein thrombosis (DVT) treatment, upper extremity thrombosis prevention, and in pregnant patients.
- Comparative studies with heparin for hemodialysis and hemofiltration show promising results, warranting further investigation.
Conclusions:
- Dalteparin sodium is a well-established LMWH with proven efficacy in preventing and treating various thrombotic events.
- Ongoing research continues to explore its potential in new clinical applications.
- Further studies are needed to confirm its recommendation for indications like hemodialysis and hemofiltration.